Provider Comparison · Last verified: May 8, 2026

Best GLP-1 Provider for Hashimoto's: 8 Picks Scored [2026]

By Weight Loss Provider Guide Research Team · An independent comparison resource for GLP-1 telehealth providers · Last verified: May 8, 2026

Affiliate disclosure: We are an independent comparison resource for GLP-1 telehealth providers. We earn a referral fee if you click through and start a program with several providers listed here. Our scoring methodology is editorial and published in full in this article. Provider features and pricing were verified from each provider's public website on May 8, 2026.

Important up front. This page is informational and is not medical advice. If you have a personal or family history of medullary thyroid cancer (MTC) or MEN 2, stop reading and talk to an endocrinologist — GLP-1s are not appropriate for you. Everything below assumes you have stable autoimmune Hashimoto's and no MTC or MEN 2 history.

The best GLP-1 provider for Hashimoto's for most readers is Ro. It's the cleanest fit for a Hashimoto's patient who wants FDA-approved medication: the broadest publicly listed FDA-approved GLP-1 lineup (Wegovy pill, Wegovy pen, Zepbound pen, Zepbound KwikPen, Foundayo, and Ozempic), an insurance concierge that handles prior-authorization paperwork, and provider-ordered metabolic lab testing through Quest when your health review warrants it.

If you have Hashimoto's, you've probably been told weight loss is "just calories in, calories out." Then you saw the thyroid cancer warning on a Wegovy ad and froze. Take a breath. We've got you.

Here's the part that ends the panic in one sentence: Hashimoto's is not the condition the boxed warning is talking about. The warning targets medullary thyroid carcinoma (MTC) and a rare inherited syndrome called MEN 2. Hashimoto's is autoimmune disease attacking different cells. We'll show you exactly why below.

If your TSH has been bouncing around or your levothyroxine dose just changed, start with thyroid-first care — Paloma Health is built for that lane. If you want live video and to pick your own provider, Sesame Care is the strongest alternative to Ro.

Check Ro Eligibility and Insurance Options →Take the 60-second match quiz

Quick Verdict — Pick Your Path in 30 Seconds

Your situation	Best first move	Why
Stable Hashimoto's, want FDA-approved meds + insurance help	Ro	Broad FDA-approved lineup, insurance concierge, provider-ordered Quest labs included in membership
Want live video visits and to choose your own provider	Sesame Care	Required video consult, broad FDA-approved formulary, transparent cash-pay pricing
TSH unstable, dose recently changed, or active hypothyroid symptoms	Paloma Health (thyroid-first)	Built around hypothyroidism and Hashimoto's; optimize labs before GLP-1
Want bundled cash-pay care with verified recurring thyroid labs	Enhance MD	TSH, CMP, lipids, and HbA1c repeated every 6 months at Quest
Stable thyroid, want flat cash-pay with same price every dose	Eden	HSA/FSA accepted, brand and compounded options, no membership fee
Personal or family history of MTC or MEN 2	Talk to an endocrinologist	Hard stop — not a provider-shopping problem

What we actually verified

Pricing on every provider's public website on May 8, 2026
FDA prescribing information for Wegovy, Zepbound, and Foundayo
The levothyroxine drug-interaction data from FDA labeling
NIDDK guidance on Hashimoto's and levothyroxine monitoring
American Thyroid Association guidance on body-weight and levothyroxine dosing
Active FDA enforcement actions affecting any provider on this page
CMS documentation for the Medicare GLP-1 Bridge launching July 1, 2026

Is GLP-1 Actually Safe If You Have Hashimoto's?

Quick answer. For most people with stable, well-managed Hashimoto's on levothyroxine, GLP-1 medications are not a contraindication. The boxed thyroid-cancer warning on every GLP-1 specifically applies to medullary thyroid carcinoma (MTC) — a rare cancer of the calcitonin-producing C-cells in the thyroid — and Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), an inherited disorder. Hashimoto's is a different condition entirely: an autoimmune attack on the follicular cells that produce thyroid hormone.

When you read "may cause thyroid tumors" in fine print, your brain skips the part where it says "in rats" and "applies to MTC and MEN 2." If you have an autoimmune thyroid condition, every word about thyroid risk hits ten times harder. That fear is rational. We're not going to gaslight you out of it.

But the warning is specific. The FDA boxed warning on semaglutide (Wegovy, Ozempic, Rybelsus) and tirzepatide (Zepbound, Mounjaro) is based on rodent studies. In high-dose rat and mouse trials, GLP-1s caused growth in C-cells. Whether that translates to humans is not established. According to current Wegovy labeling, routine calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Wegovy.

Hashimoto's attacks a different part of the thyroid entirely. It's an autoimmune attack on follicular cells (the cells that make T4) — different cells, different disease, different mechanism. According to FDA labeling, the contraindication is for personal or family history of MTC, or for patients with MEN 2. Hashimoto's, controlled hypothyroidism, levothyroxine use, Graves' disease, and benign nodules already evaluated are not on the contraindication list.

Take the 60-second Hashimoto's GLP-1 match quiz to find your best-fit provider.Take the match quiz

Hashimoto's vs MTC vs MEN 2 — What the Warning Actually Means

Quick answer. The thyroid warning on GLP-1s applies to two specific conditions: medullary thyroid carcinoma (MTC) and MEN 2. Hashimoto's is an entirely different condition — an autoimmune attack on the follicular cells that produce thyroid hormone. Hashimoto's is not on the contraindication list for any FDA-approved GLP-1.

Save this table. Show it to anyone who tells you "the medication causes thyroid cancer."

	Hashimoto's thyroiditis	Medullary thyroid carcinoma (MTC)	MEN 2
What it is	Autoimmune disease	Rare thyroid cancer	Inherited genetic syndrome
Cells affected	Follicular cells (make T4)	C-cells (make calcitonin)	Multiple endocrine glands
How common	Most common cause of hypothyroidism (~5 in 100 Americans per NIDDK)	~1–5% of all thyroid cancers (StatPearls)	About 1 in 35,000 people (NCI)
GLP-1 status	Not a contraindication	Boxed warning — do not use	Boxed warning — do not use
What you should do	Use under medical supervision; ask about TSH follow-up	Talk to an endocrinologist about other weight-loss options	Talk to an endocrinologist; GLP-1s carrying this contraindication are off the table

If you don't know whether thyroid cancer in your family was MTC or one of the more common types (papillary, follicular), ask. The GLP-1 boxed warning is specifically about MTC.

How GLP-1s Actually Interact with Levothyroxine

Quick answer. GLP-1 medications slow gastric emptying, which can affect how oral medications absorb. Wegovy and Rybelsus tablet labeling notes that levothyroxine total exposure increased by 33% when administered with oral semaglutide. This is real but routine to manage: keep your levothyroxine timing strict, plan a TSH recheck with your prescriber, and let them adjust your levothyroxine dose if labs shift.

This is the single most useful clinical fact on this page and almost no comparison site bothers to explain it clearly. GLP-1s do two things that interact with your levothyroxine:

1. They slow stomach emptying

That can give levothyroxine more time in your gut, which has been shown in oral semaglutide labeling to increase total levothyroxine exposure by 33%.

2. They cause weight loss

ATA guidance notes levothyroxine dose should be adjusted by blood-test results, and that significant changes in body weight may require dose adjustment.

The Morning Routine That Minimizes the Interaction

Time	Action	Why
6:30 AM	Wake. Take levothyroxine with a full glass of water on an empty stomach.	Levothyroxine needs an empty stomach for proper absorption.
7:00 AM	Earliest food, coffee, supplements, or other medications.	NIDDK recommends taking levothyroxine 30–60 minutes before the first meal.
Anytime that week	Weekly GLP-1 injection (Wegovy, Zepbound, Ozempic, Mounjaro).	Day-of-week and time don't materially affect the interaction for injectable GLP-1s.

Important note for oral semaglutide. Wegovy tablets, Rybelsus, and Ozempic tablets are taken on an empty stomach in the morning with a small sip of plain water, with at least 30 minutes before food, beverages, or other oral medications. Because levothyroxine also needs an empty stomach in the morning, the two compete for the same time slot. Talk to your prescriber if you want an oral GLP-1 — many patients move levothyroxine to bedtime. Foundayo (orforglipron) does not carry this restriction as a non-peptide, making it the cleanest oral GLP-1 match for levothyroxine users in 2026, and Ro carries it.

Supplements That Quietly Affect Levothyroxine

Per NIDDK guidance, take these well-separated from your levothyroxine — and note that biotin can also interfere with TSH lab results if taken too close to a blood draw:

Calcium supplements

Iron supplements

Magnesium

Biotin

Iodine / kelp

Antacids / PPIs

Soy protein

Multivitamins (with iron or calcium)

Your TSH Follow-Up Plan When Starting a GLP-1

Quick answer. Ask your prescriber for a baseline TSH (and free T4) and a follow-up plan before starting. NIDDK notes doctors usually recheck thyroid labs about 6–8 weeks after starting or changing levothyroxine. ATA guidance supports adjusting levothyroxine dose based on lab results and significant body-weight changes.

When	What to ask for	Why
Before starting	Baseline TSH and free T4	Confirms your thyroid is stable enough to add a new variable
6–8 weeks after starting (or any levo dose change)	Recheck TSH	NIDDK timeframe for retesting after starting or changing levothyroxine
3 months	TSH (free T4 if symptomatic)	Weight-loss-driven dose changes can show up here
As you lose meaningful weight	TSH + free T4, dose adjusted by results	ATA: dose should be adjusted by blood-test results and with significant body-weight changes
After weight stabilizes	Return to your usual Hashimoto's monitoring schedule	Standard care

A note on heart rhythm. Published research has examined whether older adults already on levothyroxine experience a higher rate of atrial fibrillation after starting a GLP-1, with one analysis suggesting an association — likely because thyroid-hormone over-replacement can be triggered by absorption changes if labs aren't followed. Caught early, this is a routine dose adjustment. Missed for months, it's a real risk. The takeaway is simple: use a provider that supports thyroid follow-up, and keep your endocrinologist or PCP in the loop.

The Hashimoto's-Fit Score: How 8 GLP-1 Providers Stack Up

Eight providers. One Hashimoto's-specific scorecard. Each criterion scored 0, 1, or 2 points — maximum 16.

Scoring criteria (0, 1, or 2 points each — max 16)

TSH or thyroid-relevant labs in standard or provider-ordered pre-treatment panel (catches uncontrolled thyroid before adding a gastric-emptying drug)
Live video consultation available (Hashimoto's patients often need to discuss complex history)
Provider continuity (dose adjustments need someone who knows your history)
Insurance support / prior authorization help (FDA-approved GLP-1 coverage typically requires PA paperwork)
FDA-approved formulary breadth (lower regulatory uncertainty for thyroid-anxious patients)
Levothyroxine timing or interaction guidance documented (signals clinical awareness of the actual interaction)
National lab partnership (practical for ongoing TSH retesting)
Recurring thyroid lab monitoring built in or routinely ordered (TSH should be followed when levo is in play)

Provider	TSH Labs	Live Video	Continuity	Insurance	FDA Breadth	Levo Guide	Nat'l Lab	Recurring Labs	Total	Tier
Paloma Health	2	2	2	1	1	2	1	2	13/16	Tier 1 — Best for Unstable TSH
Ro★	1	2	1	2	2	1	2	1	12/16	Tier 1 — Best Overall GLP-1 Path
Sesame Care	1	2	2	1	2	1	2	1	12/16	Tier 1 — Best for Provider Choice
Enhance MD	2	2	1	0	0	0	2	2	9/16	Tier 2 — Best Verified Cash-Pay Labs
MyStart Health	1	2	1	0	1	0	1	2	8/16	Tier 2 — Best Unlimited Access
Hims / Hers	1	1	1	1	1	0	1	1	7/16	Tier 2 — Best Mainstream Brand
Eden	1	1	0	0	1	0	1	0	4/16	Tier 3 — Best Flat-Rate Option
MEDVi	1	0	0	0	0	0	1	0	2/16	Tier 3 — See FDA notice below

Methodology and disclosure. Provider features were scored from each provider's public website on May 8, 2026. We earn a referral fee if you click through and start a program with several of the providers above. This does not change our scoring. Where a provider's intake or default lab panel was ambiguous in public copy, we scored conservatively. For final intake confirmation, ask the provider directly.

Why Paloma scored highest but isn't the default GLP-1 pick. Paloma is built specifically for thyroid care, which is why it ranks highest on a Hashimoto's-specific rubric. But Paloma is a thyroid-first lane, not a general GLP-1 program path. If your thyroid is stable and you're ready to start a GLP-1, Ro and Sesame are the right paths. Paloma is the right starting point if your TSH is unstable, your levo dose just changed, or you need a thyroid specialist before adding a GLP-1.

Check your Ro insurance coverage in 2 minutes.Check Ro Insurance Coverage →

★ Score: 12/16 · Best Overall GLP-1 Path

Why Ro Wins for Most Hashimoto's Patients

Quick answer. Ro publicly lists the broadest FDA-approved GLP-1 lineup we found in telehealth: Wegovy pill, Wegovy pen, Zepbound pen, Zepbound KwikPen, Foundayo (orforglipron), and Ozempic. Ro's insurance concierge handles prior-authorization paperwork for Wegovy and Zepbound. Ro's care model includes provider-ordered metabolic testing through Quest, included in the Ro Body membership when ordered.

Broad FDA-approved lineup. Most telehealth GLP-1 programs that carry FDA-approved options carry one or two. Ro publicly lists Wegovy pill, Wegovy pen, Zepbound pen, Zepbound KwikPen, Foundayo, and Ozempic. For someone who specifically wants FDA-approved over compounded, that's the strongest option set in the space.

Provider-ordered Quest labs included in membership. Ro's public copy says a Ro provider may order a metabolic health test, and if they do, Quest testing is included in the cost of the Ro Body membership. For someone with Hashimoto's on levothyroxine, this is exactly the situation where labs get ordered.

Insurance concierge that fights for prior auth. Ro says it handles all of the prior-authorization paperwork on your behalf for FDA-approved options like Wegovy and Zepbound. With insurance approval, your medication out-of-pocket cost can drop to your copay.

Foundayo matters specifically for Hashimoto's. Foundayo (orforglipron) is the first FDA-approved oral non-peptide GLP-1. Because it's not a peptide, it doesn't carry the same strict 30-minute fasting rule that Rybelsus and oral semaglutide do, which makes timing around your morning levothyroxine easier. Ro carries it.

24/7 messaging during dose-escalation weeks. Your TSH retest is exactly when you'll have nausea or a heart-flutter feeling and not know whether it's the GLP-1, the dose change, or your thyroid. Ro lets you message your care team without scheduling a visit.

Pricing (verify before enrolling):

$39 for the first month of Ro Body membership
$149/month ongoing on monthly billing
As low as $74/month with annual prepay paid upfront
Medication priced separately — matches LillyDirect, NovoCare, and TrumpRx
Provider-ordered Quest lab testing included in membership

Government-insurance note: Ro says it can't help coordinate GLP-1 coverage for government insurance plans (Medicare, Medicaid, Tricare). Medicare beneficiaries should review the Medicare GLP-1 Bridge section below first.

Damaging admission: Ro is not the cheapest GLP-1 program in the market. If your only goal is "the lowest possible cash-pay compounded price," Ro will feel expensive. But because Ro skips the cheap-compounded race, they can offer FDA-approved Wegovy, Zepbound, and Foundayo at the same prices as LillyDirect, NovoCare, and TrumpRx with insurance support that handles the prior-auth paperwork — which is exactly what most Hashimoto's patients should actually want.

Check Ro's Free Insurance Coverage Checker →

Get started for $39, then as low as $74/month with annual prepay. Medication billed separately.

Score: 12/16 · Best for Provider Choice

When Sesame Care Is the Better Choice

Quick answer. Sesame Care wins on two things Ro doesn't: every patient gets a required live video consultation, and you choose your own provider from a marketplace of licensed clinicians. Sesame publicly lists multiple FDA-approved options including Wegovy, Zepbound, Saxenda, and diabetes medications that may be used for weight loss such as Ozempic, Mounjaro, and Rybelsus.

Sesame is the cleaner fit if any of these describe you:

You've had a bad async-only telehealth experience and want a real human on a video call
Your Hashimoto's history is unusual — post-thyroidectomy, longstanding nodules, prior cancer that wasn't MTC — and you want a provider who can review your records carefully
You want to interview your provider before committing
You're skeptical of compounded GLP-1s and want a path that focuses on FDA-approved options

The provider-choice feature is the underrated piece. Sesame lets you read provider bios and reviews before booking. You're not assigned someone at random. For a Hashimoto's patient who's been dismissed by doctors before, that single feature is worth a lot.

Pricing (verify before enrolling):

$99 every 28 days for the program (consultation, lab work where included, unlimited messaging)
Wegovy injection $199/month for the first two months for qualifying new self-pay, then $349/month
With insurance + prior auth, brand-name GLP-1s can drop to your copay
Quest lab work included if your provider orders it — except in AZ, HI, ND, NJ, NY, OK, RI, SD, and WY
Same-day consultations available

Browse Sesame Care Providers →

Score: 13/16 · Best for Unstable TSH

When to Choose Thyroid-First Care: Paloma Health

Quick answer. If your most recent TSH was outside your target range, your levothyroxine dose changed in the last eight weeks, you have active hypothyroid symptoms (cold intolerance, fatigue, hair changes, brain fog) that aren't controlled, or you have thyroid nodules under surveillance — start with thyroid-first care before any GLP-1 program. Paloma Health is an online medical practice focused entirely on hypothyroidism and Hashimoto's.

Use the thyroid-first lane if any of the following are true: Your most recent TSH was above (or well below) your target range · Your levothyroxine dose changed in the last 8 weeks and you haven't retested yet · You're feeling cold, foggy, exhausted, or your hair is shedding and you suspect undertreated hypothyroidism · You have thyroid nodules being followed · You've never seen anyone other than a primary care doctor for your Hashimoto's.

This is the lane almost no GLP-1 comparison site mentions, and it matters because starting a GLP-1 on top of an unstable thyroid will confuse everyone. Side effects, fatigue, heart symptoms — you won't know whether they're the GLP-1, the dose escalation, your thyroid, or all three.

The honest tradeoff: Paloma is a thyroid practice first. For someone who just wants the fastest path to a GLP-1 prescription, it's not the right fit. For someone whose thyroid isn't dialed in, it's the safest possible starting point.

Not sure if your thyroid is stable enough to start a GLP-1?Take the match quiz

Score: 9/16 · Best Verified Cash-Pay Labs

When Enhance MD Fits

Quick answer. Enhance MD's public FAQ states the program lab panel includes CMP, lipids, TSH, and HbA1c, repeated every 6 months, with Quest Diagnostics used for bloodwork — making Enhance MD one of the few cash-pay providers that publicly verifies thyroid-relevant labs as part of their default protocol. Trade-off: cash-pay only, compounded medications (not FDA-approved), and per current FAQ does not accept HSA/FSA.

Enhance MD is the right fit if you: have stable Hashimoto's and stable labs; plateaued on a basic semaglutide program; want recurring metabolic and thyroid lab work without negotiating with your PCP; prefer cash-pay simplicity to insurance navigation.

Pricing: Starting at $49 first month for Core / $99 first month for Advanced, with ongoing pricing in the $212–$322/month range depending on tier.

Eden, Hims/Hers, MEDVi — Quick Takes

These providers can be legitimate paths for stable Hashimoto's patients, but they score lower on our rubric specifically because they don't publicly verify thyroid-relevant default lab inclusion or insurance prior-authorization support.

Score: 4/16 · Best Flat-Rate Option

Eden — Best Flat-Rate Cash-Pay Option

Eden is a flat-rate cash-pay program. Same price every dose, HSA/FSA accepted, no membership fees. Brand-name (Wegovy, Zepbound, Ozempic) and compounded options. Lab work is at the provider's discretion and not always required, which is why Eden scored lower on the Hashimoto's rubric.

Compounded semaglutide from $129 first month / $209 per month after on a 3-month plan; $149 first month / $229 per month on a monthly plan. Compounded tirzepatide from $249 first month / $329 per month after.

Best for: Hashimoto's patients who already have an established endocrinologist running their TSH labs and want straightforward, predictable medication access.

Check Eden Availability in Your State →

Score: 7/16 · Best Mainstream Brand

Hims / Hers — Best Mainstream Brand Option

Following the March 2026 Novo Nordisk partnership, Hims and Hers now offer broad access to FDA-approved Wegovy pill, Wegovy pen, and Ozempic. They're a strong fit for someone who wants a familiar consumer telehealth brand with FDA-approved medication and is comfortable coordinating thyroid monitoring with their existing PCP or endocrinologist.

Best for: Hashimoto's patients who want a recognized brand and are okay handling their own thyroid lab follow-up.

Score: 2/16 · See FDA Notice Below

MEDVi — Read the FDA Notice Before Enrolling

On February 20, 2026, the FDA issued a warning letter to MEDVi citing false or misleading marketing claims about its compounded GLP-1 products, including "same active ingredient" language. We are not recommending MEDVi as a top Hashimoto's pick until that issue is publicly resolved and the marketing is reverified.

If you're already enrolled with MEDVi and the program is working for you, that's between you and your prescriber. We're not telling you to leave. We're telling you that for this specific search — someone with Hashimoto's looking for a careful, conservative path — there are better-fit options listed above.

Compounded or FDA-Approved If You Have Hashimoto's?

Quick answer. For Hashimoto's patients specifically, FDA-approved medication is the more durable choice for three reasons: (1) the regulatory environment for compounded GLP-1s is contracting after the FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, (2) insurance coverage is only available for FDA-approved options, and (3) the conversation with your endocrinologist or PCP is much cleaner when you're on a medication with a complete published label.

	FDA-approved (Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo)	Compounded semaglutide / tirzepatide
FDA review	Yes — full safety, effectiveness, and manufacturing review	No — compounded medications are not FDA-approved or evaluated by FDA for safety, effectiveness, or quality
Standardized label	Yes — same prescribing info nationwide	Varies by compounding pharmacy
Insurance coverage	Yes, with prior authorization	No
Published drug-interaction data	Yes (e.g., the levothyroxine PK finding in semaglutide tablet labeling)	No comparable published data
Regulatory stability	Stable	Contracting — FDA proposed excluding semaglutide, tirzepatide, and liraglutide from 503B bulks list April 30, 2026; comment period closes June 29, 2026
Medicare GLP-1 Bridge eligible	Yes (specific drugs only)	No
Typical Hashimoto's-fit	Higher	Lower (varies by program and pharmacy)

We're not going to tell you compounded is "the same" as FDA-approved. The FDA explicitly says compounded medications are not generic versions and have not been tested for safety, effectiveness, or quality control. If you choose compounded, do it with your eyes open: pick a program that uses an accredited compounding pharmacy, ask for the Certificate of Analysis, and stay on top of your TSH labs.

If you'd rather not take on the compounded uncertainty, Ro's FDA-approved formulary is the cleanest fit.Check Ro Eligibility →

Insurance Coverage and Medicare Bridge — What to Know

Quick answer. FDA-approved GLP-1 coverage usually depends on the medication, your plan, your BMI, weight-related comorbidities, and prior-authorization rules. Many commercial plans cover Wegovy or Zepbound when you meet the FDA label criteria — generally BMI ≥30, or BMI ≥27 with a weight-related comorbidity. Beginning July 1, 2026, CMS's Medicare GLP-1 Bridge program will provide eligible Medicare Part D beneficiaries access to certain GLP-1 drugs at a $50 copay.

The medication is approved by your insurance based on FDA-label criteria. Wegovy and Zepbound are FDA-approved for chronic weight management at certain BMI thresholds. Your insurance plan decides whether to cover it based on its own formulary rules, almost always with a prior-authorization step.

The prior authorization is the leverage point. A good prior authorization includes your BMI, your full medical history, your weight history, and any weight-related comorbidities. Plans approve when this story is told well. Plans deny when the paperwork is sloppy. That's why a provider with a concierge service that handles the PA is genuinely worth the membership cost.

HSA and FSA still work for cash-pay. If your insurance won't cover the medication, you can usually use HSA or FSA for the program fee and the medication. Verify acceptance with each provider — Enhance MD's current FAQ states it does not accept HSA/FSA at all.

The Medicare GLP-1 Bridge (starting July 1, 2026)

According to CMS documentation, the Medicare GLP-1 Bridge is a demonstration program running from July 1, 2026 through December 31, 2027. Eligible Medicare Part D beneficiaries can access certain GLP-1 drugs at a $50 monthly copay.

Eligible drugs

Foundayo, Wegovy injection, Wegovy tablets, Zepbound KwikPen

Not included

Zepbound vial and Zepbound single-dose pen

Requirements

Prior authorization plus specific BMI and comorbidity criteria

The Bridge does not cover compounded medications — yet another reason FDA-approved is the more durable choice for ongoing care.

Run a 2-minute Insurance Coverage Check on Ro (best for commercial insurance and cash-pay brand shoppers; Medicare beneficiaries review the Bridge eligibility criteria above first).Run Insurance Coverage Check →

What to Ask Any GLP-1 Provider Before You Commit

Quick answer. Before paying any GLP-1 telehealth provider, confirm five things specific to your Hashimoto's care: (1) Will baseline TSH and free T4 be checked or reviewed before I start? (2) When should I recheck thyroid labs after I start? (3) Can I message the provider during a TSH retest week if I have palpitations or symptoms? (4) Will the provider coordinate with my endocrinologist if I ask? (5) Can the provider give me clear timing guidance for levothyroxine?

About your thyroid

Your current Hashimoto's diagnosis date
Your current levothyroxine dose
Your last 2 TSH and free T4 results, with dates
Any TPO antibody result you have
Whether your dose has changed in the last 8 weeks
Any thyroid nodules or ultrasound history
Personal or family history of medullary thyroid cancer or MEN 2 (be specific — don't generalize "thyroid cancer")

About your other health

All current medications and supplements (calcium, iron, biotin, iodine especially)
Pregnancy or pregnancy planning status
Any history of pancreatitis, gallbladder disease, kidney disease, gastroparesis, or diabetic retinopathy
Diabetes medications (insulin or sulfonylureas — these may need adjustment when you start a GLP-1)

The exact question to ask your provider:

"Given my Hashimoto's and current levothyroxine dose, do you recommend baseline TSH and free T4 before starting a GLP-1, and when should I recheck if I lose meaningful weight or change levothyroxine dose?"

A confident provider will answer this without hesitation. A vague answer is information about whether you should pay them.

See providers that include lab testing →

The Three Tiers — Hard Stops, Extra Caution, and Not Disqualifiers

Hard Stops — Do Not Start a GLP-1

Personal or family history of medullary thyroid carcinoma (MTC)
MEN 2 syndrome
Severe allergy to GLP-1 medication ingredients
Pregnancy or breastfeeding (semaglutide should be discontinued at least 2 months before a planned pregnancy due to its long half-life)

If any of these apply, this guide is not for you. Talk to an endocrinologist about other paths.

Extra Caution — Provider Must Screen Carefully Before Starting

Thyroid nodules under surveillance
New neck mass, hoarseness, trouble swallowing, or shortness of breath (get evaluated first)
TSH currently outside your target range
Levothyroxine dose changed in the last 8 weeks
Personal history of pancreatitis or gallbladder disease
Severe GI disease or gastroparesis
Diabetic retinopathy
Significant kidney disease
Currently taking insulin or a sulfonylurea (may need dose adjustment to avoid hypoglycemia)

These don't disqualify you. They mean you need a provider who will screen and monitor — not a provider who will rubber-stamp.

Not Automatic Disqualifiers — Proceed Under Medical Supervision

Hashimoto's thyroiditis
Stable, controlled hypothyroidism on levothyroxine
Most benign thyroid nodules already evaluated by an endocrinologist
Prior papillary or follicular thyroid cancer (different from MTC — confirm the type with your prescriber)
Graves' disease (currently controlled)
General "thyroid problems" that turn out to be stable hypothyroidism

If you're in this category, the GLP-1 conversation is on the table. Pick a provider that fits your situation using the scorecard above.

How We Ranked GLP-1 Providers for Hashimoto's

Quick answer. We ranked providers on what matters specifically to a Hashimoto's patient: thyroid-relevant lab inclusion, live clinical access, insurance support, FDA-approved formulary breadth, levothyroxine timing guidance, and recurring monitoring. We deliberately did not rank by affiliate payout. Several lower-paying providers (Sesame, Paloma) ranked at or near the top because the clinical fit for Hashimoto's was stronger.

We pulled provider features from each provider's public website on May 8, 2026. We scored each provider 0, 1, or 2 points on each of 8 criteria for a maximum of 16. The criteria were chosen based on what matters when a Hashimoto's patient on levothyroxine starts a GLP-1 — specifically, that thyroid labs should be followed when significant body-weight changes or absorption shifts occur (per ATA and NIDDK guidance), and that levothyroxine timing should be addressed because of the gastric-emptying interaction (documented in oral semaglutide labeling).

We did not score on:

Affiliate payout (deliberately)
Marketing reach
Trustpilot rating (subject to manipulation)
Compounded vs FDA-approved as a binary

We did flag:

Active FDA warning letters where they exist (MEDVi, February 20, 2026)
Recent regulatory actions affecting compounded supply (April 30, 2026 503B bulks list proposal)

We will refresh this page monthly during 2026 because the regulatory landscape (compounding policy, Medicare Bridge launch, FDA warning letter resolutions) is moving fast.

Frequently Asked Questions

For most people with stable, well-controlled Hashimoto's on levothyroxine, GLP-1 medications are not a contraindication. According to FDA labeling, the boxed thyroid-cancer warning specifically applies to medullary thyroid carcinoma (MTC) and MEN 2 — different conditions from autoimmune Hashimoto's. Use under medical supervision and ask your prescriber about a TSH follow-up plan.

Hashimoto's is not on the contraindication list in Wegovy's FDA labeling. Plan for a TSH recheck after starting because absorption changes and weight loss may shift your levothyroxine dose requirement. Patients with personal or family history of MTC or MEN 2 should not take Wegovy.

Yes, modestly — and the data is from oral semaglutide labeling specifically. According to FDA labeling for Wegovy and Rybelsus tablets, levothyroxine total exposure increased by 33% when administered with oral semaglutide. Your prescriber may need to adjust your levothyroxine dose. Recheck TSH after starting.

Hypothyroidism — including the autoimmune form (Hashimoto's) — is not on the contraindication list in Ozempic's FDA labeling. Your TSH should be controlled before you start, and your prescriber should plan a follow-up after starting. Ozempic is FDA-approved for type 2 diabetes and is sometimes prescribed off-label for weight loss.

Hashimoto's is not on the contraindication list in Zepbound's FDA labeling. Patients with personal or family history of MTC, or with MEN 2, should not take Zepbound — those are different conditions from Hashimoto's. Standard TSH follow-up applies.

The boxed warning is based on rodent studies showing thyroid C-cell tumors at high doses; whether this translates to humans is not established. Per current Wegovy labeling, routine calcitonin monitoring or thyroid ultrasound is of uncertain value for early MTC detection in patients treated with Wegovy. Hashimoto's is a different condition and not the labeled contraindication.

There is no single best medication for Hashimoto's specifically — the best choice depends on your insurance, your levothyroxine status, and your provider's monitoring infrastructure. For most stable Hashimoto's patients with insurance, FDA-approved Wegovy or Zepbound through a provider that supports thyroid follow-up (Ro or Sesame Care) is the strongest path.

NIDDK notes thyroid labs are typically rechecked about 6–8 weeks after starting or changing levothyroxine. ATA guidance supports adjusting levothyroxine dose based on lab results and significant body-weight changes. Ask your prescriber for a baseline plus a follow-up plan, and recheck as you lose meaningful weight.

Coverage depends on your specific plan, your BMI, your documented weight-related comorbidities, and prior-authorization rules. The general FDA-label criteria are BMI ≥30, or BMI ≥27 with a weight-related comorbidity. Hashimoto's-driven hypothyroidism with weight gain can be part of that medical history, but each plan sets its own rules. A provider with an insurance concierge speeds up the paperwork.

Yes. Even though most telehealth providers don't require it, looping in your endocrinologist before starting a GLP-1 is the gold standard for Hashimoto's care. Bring this guide's checklist to that conversation.

Hashimoto's doesn't make compounded GLP-1s automatically inappropriate, but compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. For safety-anxious thyroid patients, FDA-approved Wegovy or Zepbound through Ro or Sesame Care is the more durable choice — both for clinical confidence and for insurance coverage.

If your nodule has been evaluated by an endocrinologist and is benign or under routine surveillance, talk to your prescriber about whether a GLP-1 is appropriate. If you have a new neck lump, hoarseness, trouble swallowing, or shortness of breath, get evaluated before starting a GLP-1 — FDA labels specifically flag those symptoms.

The Bottom Line — What to Do Today

Most readers of this guide land in one of three buckets. Use the bucket that fits.

If your Hashimoto's is stable on levothyroxine and you have commercial insurance:

Run the free Insurance Coverage Checker on Ro. Ro's concierge handles the prior-authorization paperwork, and with approval your medication out-of-pocket cost can drop to your copay. The Ro Body membership is $39 the first month, then as low as $74/month with annual prepay.

Check Ro Insurance Coverage in 2 Minutes →

If you want to choose your own provider and want a real video visit:

Sesame Care is $99 every 28 days, includes the consultation and lab work in most states, gives you a broad FDA-approved formulary to choose from, and lets you browse providers before booking.

Browse Sesame Care Providers →

If your TSH isn't stable yet, your levo dose just changed, or you're not sure where you stand:

Don't start with the fastest GLP-1 program. Take the matching quiz to route to the right path — sometimes that's a thyroid-first consult through Paloma, sometimes it's a careful telehealth program with labs, sometimes it's a conversation with your existing endocrinologist.

Take the free 60-second matching quiz

Why This Page Is Different from What's Already Ranking

We built a Hashimoto's-specific provider-fit framework. The 8 criteria above are autoimmune-thyroid-specific. We scored conservatively where public copy was ambiguous and we said so out loud. That's the moat: verification discipline, not overclaiming.

We included the regulatory reality. The April 30, 2026 FDA 503B compounding proposal, the February 20, 2026 MEDVi warning letter, the July 1, 2026 Medicare GLP-1 Bridge launch, the March 2026 Hims/Hers Novo Nordisk partnership — these are all moving pieces that materially change the answer to "which provider?" Most pages haven't updated since 2025.

We routed wrong-fit readers away from the high-paying recommendation. If your TSH is unstable, the right answer is Paloma or your endocrinologist — not a fast Ro signup. We said that out loud because it's true, and because the right reader trusts you more when you're willing to lose them.

Sources We Consulted

FDA prescribing information for Wegovy (DailyMed), Zepbound, Ozempic, and Foundayo

FDA postmarket safety communications on compounded GLP-1s

FDA proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list (April 30, 2026)

FDA warning letter to MEDVi LLC (February 20, 2026)

NIDDK guidance on Hashimoto's disease and levothyroxine

American Thyroid Association guidance on body-weight and levothyroxine dosing

CMS documentation for the Medicare GLP-1 Bridge program

Provider feature claims sourced from each provider's public website as of May 8, 2026

Medical disclaimer: This page is informational and is not medical advice. Consult a licensed healthcare professional before starting any prescription weight-loss program. If you have a personal or family history of medullary thyroid carcinoma or MEN 2, do not start a GLP-1 medication.